
Tobias Derfuss

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1644343/publications.pdf Version: 2024-02-01



TORIAS DEDEUSS

#	Article	IF	CITATIONS
1	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Multiple Sclerosis Journal, 2022, 28, 429-440.	3.0	40
2	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39
3	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Multiple Sclerosis Journal, 2022, 28, 132-138.	3.0	31
4	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	3.0	21
5	Selective inhibition of antiâ€MAG IgM autoantibody binding to myelin by an antigenâ€specific glycopolymer. Journal of Neurochemistry, 2020, 154, 486-501.	3.9	17
6	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
7	PARP-1 deregulation in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989460.	1.0	10
8	Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. Multiple Sclerosis Journal, 2021, 27, 439-448.	3.0	8
9	The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732090795.	1.0	4
10	Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	3
11	PML with dimethyl fumarate—No convincing case against natalizumab. Multiple Sclerosis Journal, 2019, 25, 1687-1688.	3.0	1
12	All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: Commentary. Multiple Sclerosis Journal, 2022, , 135245852210975.	3.0	0